Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silevertinib + Temozolomide in Newly Diagnosed Glioblastoma
NCT07326566Phase 2Recruiting
- Sponsor
- Black Diamond Therapeutics
- Start
- May 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of silevertinib in glioblastoma (GBM), sponsored by Black Diamond Therapeutics. Started May 2026; status: recruiting.
02
Drugs
silevertinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07326566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07326566.